Recent transactions

December 2025
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in VALEARA - a leading provider of ambulatory mental healthcare services in Germany

 

VALEARA
November 2025
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in AAC Praxisberatung - the leading software-based service provider for controlling and auditing of billing for physicians in Germany's statutory health insurance (GKV) system

 

download 25
October 2025
Germany

Buy-side M&A support

ISP acted as the exclusive buy-side M&A advisor for the acquisition of DiaMed Beratungsgesellschaft für pharmazeutische Unternehmen – a well-established German Regulatory Affairs and Pharmacovigilance consultancy

 

Diamed
July 2025
Germany

Commercial Vendor Due Diligence

ISP performed the Commercial VDD for the seller of Pentapharm AG – a leading supplier of biological agents for pharmaceutical and diagnostic applications with unique expertise in the field of haemostasis

 

Picture4
July 2025
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in KLmed – a leading personnel service provider for medical healthcare facilities

 

KLmed
July 2025
Germany, Spain

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in Bioarray – a leading Spanish diagnostic and research laboratory specializing in advanced genetic testing

Bioarray
April 2025
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in Paracelsus' rehab division – a leading German rehabilitation provider

Picture4
January 2025
Germany, UK

Buy-side M&A support

ISP acted as the exclusive buy-side M&A advisor for the acquisition of S-cubed – a well-established UK-based Regulatory Affairs and Quality Assurance consultancy

S-cubed
January 2025
Germany, Sweden

Buy-side M&A support

ISP acted as exclusive buy-side M&A advisor for the acquisition of Quantify – a leading player in real-world evidence generation, health economics & outcomes research

Picture11
October 2024
Germany, Lithuania

Buy-side M&A support

ISP acted as exclusive buy-side M&A advisor for the acquisition of Biomapas – a leading player in pharmaceutical clinical research

Biomapas
July 2024
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in DMRZ – a leading cloud-based billing software for other healthcare providers

DMRZ
July 2024
Germany

Vendor Due Diligence

ISP acted as sole commercial advisor for the Vendor CDD Otto LSE – the leading EPC provider for GMP pharma production facilities in Central Europe

Otto LSE
July 2024
Germany, Israel

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in A.R.C. Laser and Neolaser – two leading medical laser manufacturers

A.R.C. Laser
May 2024
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in VAMED – a major European stationary rehab provider

Vamed Logo
March 2024
USA

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in Dermlite – the leading US Dermatoscope device manufacturer

Dermlite
December 2023
Switzerland

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in SDS – leading ceramic dental implant manufacturer

Swiss Dental Solutions
November 2023
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in Imes-icore – leading dental milling machine manufacturer

imes-icore
October 2023
Germany

Vendor Due Diligence

ISP acted as sole commercial advisor for the Vendor CDD Academia – leading DACH genetics/pathology laboratory platform

Academia
October 2023
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in CRS medical GmbH – a leading supplier of non-point-of care defibrillators

CRS medical
August 2023
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in MLase – the leading CDMO for medical excimer lasers

MLase
July 2023
Bulgaria, Slovenia

Buy-side M&A support

ISP acted as exclusive buy-side strategic transaction advisor for the Series B investment into Geneplanet – a preventive genetic testing player

Gene Planet
April 2023
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in Sonnen Gesundheitszentrum – a leading laboratory for hemostaseology in Germany

Sonnen Gesundheits Zentrum
March 2023
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in Genetikum – the leading laboratory for human genetics in Germany

Genetikum
October 2022
France and UK

Strategic Advisor

ISP acted as strategic advisor to Laboratoire XO – a pharma co. focused on mature market authorizations, in their majority acquisition by Stanley Capital

LaboratoireXO
September 2022
Austria

Commercial Due Diligence

ISP acted as sole commercial advisor for an investment in Heintel Medizintechnik – Austrians leading hospital focused MedTech distributor

Heintel
August 2022
Germany

Commercial Due Diligence

ISP acted as sole commercial advisor for an anchor investment in Nexus – a leading hospital information system provider

Nexus AG